Robert Harrington MD
Interventional Cardiology
Stephen and Suzanne Weiss Dean, Weill Cornell Medicine and Provost for Medical Affairs, Cornell University
Join to View Full Profile
1300 York Ave F113New York, NY 10065
Phone+1 212-746-6005
Dr. Harrington is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke University HospitalFellowship, Cardiovascular Disease, 1990 - 1993
UMass Chan Medical SchoolResidency, Internal Medicine, 1986 - 1989
Tufts University School of MedicineClass of 1986
Certifications & Licensure
CA State Medical License 2012 - 2025
NY State Medical License 2023 - 2025
NC State Medical License 1993 - 2017
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Fellow (FACC) American College of Cardiology
Clinical Trials
- A Clinical Trial to Demonstrate the Efficacy of Cangrelor Start of enrollment: 2006 Apr 01
- Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. Start of enrollment: 2006 Sep 01
- A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome Start of enrollment: 2006 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS).C Michael Gibson, M Cecilia Bahit, Roxana Mehran, Shamir R Mehta, Rasha Al Lamee
American Heart Journal. 2025-07-01 - Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Cor...P Gabriel Steg, Michael Szarek, J Wouter Jukema, Deepak L Bhatt, Vera A Bittner
Circulation. 2025-04-08 - Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial.Gregory G Schwartz, Michael Szarek, J Wouter Jukema, Christa M Cobbaert, Esther Reijnders
Diabetes Care. 2025-04-01
Journal Articles
- Alirocumab and Cardiovascular Outcomes After Acute Coronary SyndromeVera A Bittner, Kenneth W Mahaffey, Deepak L Bhatt, Robert A Harrington, Gregory G Schwartz, Matthew T Roe, The New England Journal of Medicine
- Impact of Lesion Complexity on Peri-Procedural Adverse Events and the Benefit of Potent Intravenous Platelet Adenosine Diphosphate Receptor Inhibition After Percutaneo...Gregg W Stone, Matthew J Price, Philippe Genereux, C Michael Gibson, Deepak L Bhatt, Robert A Harrington, Kenneth W Mahaffey, European Heart Journal
- Effects of Genetic Variation in Protease Activated Receptor 4 After an Acute Coronary Syndrome: Analysis from the TRACER TrialPaolo Fortina, David J Moliterno, Robert A Harrington, Kenneth W Mahaffey, ScienceDirect
Press Mentions
Despite Obstacles, Women Are Uniquely Positioned to Flourish in MedicineApril 14th, 2025- Medical Students Celebrate Their Future with Match Day SuccessesMarch 21st, 2025
- This Week in CardiologyMarch 14th, 2025
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
